GcMAF

This video discusses immunotherapy through the lens of lung cancer. It is linked as general cancer interest rather than a featured protocol overview because it is disease-specific and hosted outside the mainstream patient education channels.

Overview

This video features David Noakes explaining how first immune GcMAF (Gc protein-derived macrophage activating factor) is used in the treatment of prostate cancer. He describes prostate cancer as a slow-progressing disease typically requiring about eight months of treatment with GcMAF to observe significant changes.

Noakes highlights that during the initial phase of treatment, immune system rebuilding occurs, with natural killer cells (referred to as "nagalase") decreasing after three weeks and markers such as PSA initially rising within the first three months. He critiques PSA as a poor marker for prostate cancer progression and recommends monitoring follicle stimulating hormone (FSH) levels instead, ideally aiming for values above 10.

He warns against hormone therapies that lower FSH below 1, which can irreversibly damage the adrenal gland's control over the prostate. Noakes advocates for GcMAF combined with DCA (dichloroacetate) as a safer alternative to chemotherapy, citing a case where PSA dropped from 746 to 10.5 within five months of GcMAF treatment.

Regarding side effects, Noakes states that genuine GcMAF has no direct side effects since it is a naturally occurring molecule in humans and other mammals. However, side effects may arise from immune system activation, such as hot flushes or, in rare cases, inflammation and swelling of tumors causing complications like increased intracranial pressure, which may require dose adjustment.

Source Information

This content is derived from a 2012 YouTube video titled "Prostate Cancer and GcMAF" featuring David Noakes. The transcript provides direct quotations and detailed explanations about GcMAF's role in prostate cancer treatment, immune response, hormone markers, treatment timelines, and safety considerations.

Overview

This video presents time-lapse microscopy footage demonstrating the destruction of human breast cancer cells (MCF7) by macrophages after exposure to First Immune's GcMAF. The footage shows cancer cells initially arranged in a corrugated monolayer and as irregular "fingers" above this layer. Macrophages, initially inactive, begin to destroy the cancer cells following the addition of GcMAF.

Over approximately 60 hours, the cancer monolayer changes from a corrugated to a smooth surface as macrophages consume the cancer cells starting from the bottom left. Subsequently, the irregular cancer cell "fingers" are also destroyed. This visual evidence is part of routine assays performed on GcMAF batches in First Immune's laboratories.

Scientific Context and Claims

• The video claims to be a worldwide first in showing GcMAF’s effects on cancer cells via time-lapse microscopy.
• It references a peer-reviewed research paper titled "Multifaceted immunotherapeutic effects of GcMAF on human breast cancer cells," presented at the January 2013 Immunology Conference in San Diego.
• Additionally, it cites confirmation from a 2012 publication in the journal Anticancer Research that studied vitamin D-binding protein-derived macrophage-activating factor effects on breast cancer cells, which used First Immune’s GcMAF in their experiments.
• First Immune states that their GcMAF is supplied to approximately 5,000 patients and 300 doctors across 30 countries.

Limitations and Source Information

No transcript is available for this video. The description and claims are based on the promotional content provided by First Immune (gcmaf.eu). The video and accompanying text present GcMAF as an immune-based approach to cancer treatment, specifically showing macrophage activation leading to cancer cell destruction in vitro. However, the video itself does not provide detailed clinical data or independent verification beyond the referenced publications.

Source Information

This media record is a 2-minute 16-second YouTube video titled "Cancer cells destroyed by First Immune GcMAF (gcmaf.eu)," uploaded on October 21, 2012. It is hosted on the YouTube platform and linked to topics including bladder and pancreatic cancer, as well as protocols involving GcMAF and radiation exposure remediation.

The video is produced by First Immune, a company that manufactures and supplies GcMAF, and it features time-lapse microscopy footage from their laboratories. The content is promotional and highlights their research and product use in cancer-related immune therapies.

Overview

Topic Context

This video is connected with Bladder Cancer, GcMAF. It can be used as supporting media for those topic pages, especially when a visitor wants a video overview, presentation, interview, lecture, or visual explanation rather than a written source.

Source Information

• Platform: ITV News / The One Show clip
• Type: video link
• Date: 2015-05-07
• Source URL: https://www.itv.com/news/channel/update/2015-05-07/watch-gcmaf-founder-defends-cancer-drug-in-horrible-interview/
• Linked topics: Diseases: Bladder Cancer; Protocols: GcMAF

Overview

In this video, Dr. Russell LivWell shares his approach to integrative cancer treatment focused on restoring the immune system. Since 2014, he has developed a six-month program that combines laboratory-prepared GC MAF injections, personalized vitamin compounds, and gut microbiome recolonization with beneficial bacteria. This multi-faceted protocol aims to activate immune cells in the bone marrow within hours and support overall immune restoration.

Dr. LivWell also notes that secondary autoimmune diseases such as lupus and colitis have shown improvement or remission in his patients after three to four months of treatment. Building on these observations, he has created a cancer and autoimmune disease prevention program for 2024 that emphasizes natural, science-based methods without side effects.

Key Components of the Treatment Program

• GC MAF injections: Home-administered injections designed to activate immune cells rapidly.
• Personalized vitamin compounds: Tailored nutrient dosing to support immune function.
• Gut microbiome restoration: Recolonization with beneficial bacteria to enhance immune health.

Source Information

This content is sourced from a 2015 YouTube video titled "Integrative Cancer Treatment: NAGALASE, GC MAF" featuring Dr. Russell LivWell. The video includes a transcript of Dr. LivWell’s presentation describing his clinical experience and treatment protocols. The video is referenced by GcMAF information hubs and relates to cancer-related diseases and integrative protocols.

Overview

Topic Context

This video is connected with Bladder Cancer, GcMAF. It can be used as supporting media for those topic pages, especially when a visitor wants a video overview, presentation, interview, lecture, or visual explanation rather than a written source.

Source Information

• Platform: Frequency Foundation
• Type: video link
• Date: 2016-02-07
• Source URL: https://staging.frequencyfoundation.com/2016/02/07/gcmaf-and-nagalase/
• Linked topics: Diseases: Bladder Cancer; Protocols: GcMAF